India, November 14: Diabetes is a metabolic disorder of multiple aetiology characterized by chronic hyperglycemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action or both. International Diabetes Federation (IDF) have estimated that the prevalence of diabetes worldwide is 10.5%. If current trends continue, 783 million adults will have diabetes by 2045. India is home to 74.2 million diabetics, second highest in the world.

World Diabetes Day is the global awareness campaign focusing on diabetes mellitus and is held on 14th November each year. Millions of patients worldwide do not have access to diabetes care and many of them require ongoing care to manage diabetes and avoid complications.

One of the fundamental components of diabetes care includes access to insulin that 73 million Indians must take daily to manage their diabetes & prevent complications. However, even today affordability of insulin still remains a challenge which is one of the major reason for non-adherence. It is observed that because of non-adherence 45% of patients with T2DM fail to achieve adequate glycemic control (HbA1c <7%) and this may result in the complications of the disease observed in the long run. Hence, providing access to insulin therapy by addressing the challenges of non-affordability and accessibility becomes very important for management of diabetes.

Wockhardt, India’s one of the leading pharmaceutical company has been a pioneer in development of indigenous insulin. Wockhardt was the 1st Indian company to manufacture Insulin in India and has been helping Indian patients access the insulin at an affordable price for last 20 years. Moreover, Wockhardt is the only company that introduced the concept of 50% extra insulin in its insulin range of products – WOSULIN (human insulin) and GLARITUS (insulin glargine).

After launching quality bio similar insulin’s Glaritus and Wosulin which have been helping Indian diabetes patients to break the affordability barrier, Wockhardt has forayed into Sitagliptin segment with Sitawok which is one of the most economical Sitagliptin brand with global quality.

We at Wockhardt believe that quality medicine is not a privilege but a necessity, therefore it is important to make quality medicines at affordable prices and we are striving to achieve the same every day and help life win!

If you have any objection to this press release content, kindly contact [email protected] to notify us. We will respond and rectify the situation in the next 24 hours.





Source link

Leave comment

Your email address will not be published. Required fields are marked with *.